Apellis Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Apellis Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2016 to Q3 2024.
  • Apellis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$57.4M, a 59% increase year-over-year.
  • Apellis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$250M, a 58.7% increase year-over-year.
  • Apellis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$529M, a 18.9% increase from 2022.
  • Apellis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$652M, a 12.6% increase from 2021.
  • Apellis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$746M, a 116% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$250M -$57.4M +$82.8M +59% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 -$333M -$37.7M +$84.4M +69.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-05
Q1 2024 -$417M -$66.4M +$111M +62.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-05
Q4 2023 -$529M -$88.6M +$77.4M +46.6% Oct 1, 2023 Dec 31, 2023 10-K/A 2024-02-29
Q3 2023 -$606M -$140M +$51M +26.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$657M -$122M +$33.9M +21.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-05
Q1 2023 -$691M -$178M -$38.8M -28% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-05
Q4 2022 -$652M -$166M -$18.1M -12.2% Oct 1, 2022 Dec 31, 2022 10-K/A 2024-02-29
Q3 2022 -$634M -$191M +$4.3M +2.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$638M -$156M +$63.2M +28.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-01
Q1 2022 -$702M -$139M +$44.7M +24.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-01
Q4 2021 -$746M -$148M -$226M -289% Oct 1, 2021 Dec 31, 2021 10-K/A 2024-02-29
Q3 2021 -$520M -$196M -$59.9M -44.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$460M -$219M -$101M -84.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$360M -$184M -$14.8M -8.79% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$345M $78.3M +$191M Oct 1, 2020 Dec 31, 2020 10-K 2021-02-25
Q3 2020 -$536M -$136M -$65.9M -94.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$470M -$119M -$47.5M -66.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$423M -$169M -$118M -234% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
Q4 2019 -$305M -$113M -$76.8M -211% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$228M -$69.8M -$33.9M -94.1% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 -$194M -$71.1M -$37.8M -113% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 -$156M -$50.6M -$28.8M -133% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 -$128M -$36.5M -$18.2M -99.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$109M -$36M -$24.4M -211% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$84.9M -$33.3M -$21.2M -175% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$63.7M -$21.7M -$12.7M -140% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$51M -$18.3M -$11.6M -176% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-26
Q3 2017 -$39.4M -$11.6M -$4.36M -60.5% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-26
Q2 2017 -$35M -$12.1M -$4.83M -66.2% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-26
Q1 2017 -$30.2M -$9.05M -$3.05M -50.9% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-26
Q4 2016 -$27.1M -$6.62M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-19
Q3 2016 -$7.21M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-19
Q2 2016 -$7.29M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-19
Q1 2016 -$6M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.